High-Dose Fentanyl Patch for Cancer Pain

References

1. ↵
   Muijsers BR, Wagstaff AJ. Transdermal fentanyl—an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61: 2289–307.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manag 2000; 9: 8–15.

   OpenUrl
3. ↵
   Skaer TL. Management of pain in the cancer patient. Clin Ther 1993; 15: 638–49.

   OpenUrlPubMedWeb of Science
4. ↵
   Allan L, Hays H, Jensen NH, et al. Randomized crossover trail of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322: 1154–8.

   OpenUrlAbstract/FREE Full Text
5. ↵
   Sloan PA, Moulin DE, Hays H. A clinical evaluation of the transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 1998; 16: 102–11.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Calis KA, Kohler DR, Corso DM. Transdermally administrated fentanyl for pain management. Clin Pharm 1992; 11: 22–36.

   OpenUrlPubMedWeb of Science
7. ↵
   Ahmedzai S. New approaches to pain control in patients with cancer. Eur J Cancer 1997; 33 Suppl 6: S8–14.
8. ↵
   Duragesic (Fentanyl transdermal system) full prescribing information. New Brunswick (NJ): Janssen Pharmaceutica; 2001.
9. ↵
   Bonica JJ. Treatment of cancer pain: current status and future needs. In: Fields HL, Dubner R, Cervero F, editors. Advances in pain research and therapy. Vol 9. New York (NY): Raven Press; 1985. p. 589–616.
10. ↵
    Moynihan TJ. Use of opioids in the treatment of severe pain in terminally ill patients; dying should not be painful. Mayo Clin Proc 2003; 78: 1397–579.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol Oncol Clin North Am 2002; 16: 527–41.

    OpenUrlCrossRefPubMed
12. ↵
    Billings JA. Palliative care. BMJ 2000; 321: 555–8.

    OpenUrlFREE Full Text
13. ↵
    Cleary JF. Cancer pain management. Cancer Control 2000; 7: 120–31.

    OpenUrlPubMed
14. ↵
    Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med 2001; 15: 309–21.

    OpenUrlAbstract/FREE Full Text
15. ↵
    Lehr VT, Renaud EA. High transdermal fentanyl requirements in a patient with chronic cancer pain. Ann Pharmacother 1993; 27: 575–8.

    OpenUrlPubMed
16. ↵
    Simmonds MA, Richenbacher J. Transdermal fentanyl: long-term analgesic studies. J Pain Symptom Manage 1992; 3 Suppl: S36–9.
17. ↵
    Bleeker CP, Bremer RC, Dongelmans DA, van Dongen RTM, Crul BJ. Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain: a case report. Eur J Pain 2001; 5: 325–9.

    OpenUrlCrossRefPubMedWeb of Science